LWCFA
PTCT icon

Loring Wolcott & Coolidge Fiduciary Advisors’s PTC Therapeutics PTCT Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-142
Closed -$9K – 601
2020
Q4 		$9K Buy
+142
New +$8.37K ﹤0.01% 588

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's PTCT Position: Q1 2021 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of PTC Therapeutics (PTCT) in Q1 2021, closing a stake of 142 shares — an estimated $9K sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in PTCT in Q4 2020 and held it in 1 quarter. The position peaked at $9K in Q4 2020. 208 funds tracked by Wall St. Rank hold PTCT as of Q1 2021.

  • Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining PTC Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Loring Wolcott & Coolidge Fiduciary Advisors sold 142 PTC Therapeutics shares in Q1 2021, an estimated $9K.
  • Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in PTC Therapeutics in Q4 2020 and held it in 1 quarter.
  • Loring Wolcott & Coolidge Fiduciary Advisors's PTC Therapeutics position peaked at $9K in Q4 2020.
  • 208 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2021.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q1 2021, filed 14 Apr 2021.